Featured Education

Advances in Non-Hodgkin Lymphoma Care: Navigating New and Emerging Treatments

Click here to learn more

Checkpoint Conversations: Integrating Immune Checkpoint Inhibitors in Hodgkin Lymphoma

Click here to learn more

Making the Right Selection: Expert Guidance on Treatment Sequencing of T-cell Mediated Therapies

Click here to learn more

A Case-based Challenge of CART in NHL + MM

Click here to learn more

Taking a Team Approach: Community-based Practices at the Forefront of NHL and HL Care

Click here to learn more

Integrating Novel Therapies in Hemophilia in the Midst of Bridging Health Inequities

Click here to learn more

On Demand Activities

More results...

Therapeutics Areas
Learner Specialties
Expires After
  • On-Demand
Taking a Team Approach: Community-based Practices at the Forefront of NHL and HL Care
  • Credit: 0.25hr(s)
  • AAPA, ABIM, CME, CPE, MOC, NCPD, Royal College MOC 
  • May 15, 2024 — 
  • May 14, 2025
  • Therapeutic Areas: Pan Tumor, Pathology, Pharmacy
  • Specialties: Pathology, Pharmacy
  • Location: Internet Activity Enduring
In this third episode, “Taking a Team Approach: Community-based Practices at the Forefront of NHL and HL Care,” from the 4-part series Med Table Talk, “The Power of the Community: Translating Innovations into Care in NHL and HL,” join expert faculty and special guest, Caitlin Murphy, DNP to discuss community-based practices for the treatment of NHL and HL. This episode will focus on how to best evaluate patients for and increase participation in clinical trials. Additional conversations will revolve around assessing patient quality of life, recognizing social determinants of health that impact patient care, and recognizing healthcare barriers and inequities in your own patient population. This episode will conclude with a conversation about misperceptions for CAR T-cell therapy and how to best coordinate care for patients receiving either CAR T-cell therapy or bispecific antibody therapy.
Access Course
  • On-Demand
Keeping Up with CAR T-cell Therapy: A Case-based Challenge of CART in NHL + MM
  • Credit: 1.50hr(s)
  • ILNA, NCPD
  • May 15, 2024 — 
  • May 14, 2025
  • Therapeutic Areas: Hematologic Oncology, Hematology, Oncology
  • Specialties: Hematology, Lymphoma, Oncology
  • Location: Internet Activity Enduring
Nurses are often at the front lines of clinical care and as such, are perfectly positioned to bridge the gap between evolving clinical evidence and patient-centered care in Non-Hodgkin’s Lymphoma (NHL) and Multiple Myeloma (MM). This dynamic educational activity will equip nursing professionals with the critical skills to integrate the latest advancements in CAR T-cell therapy into practice, ensuring alignment with NCCN guidelines and patient preferences. Through interactive case studies and expert-led discussions, you’ll be empowered to manage complex treatment scenarios, deliver comprehensive patient education, and navigate even the trickiest treatment-related challenges.
Access Course
  • On-Demand
Improving Survival in First-Line Metastatic NSCLC with Dual Checkpoint Blockade: Exploring Recent Data and Treatment Strategies / Activity 1
  • Credit: 0.50hr(s)
  • AAPA, CME, CPE, NCPD
  • February 17, 2023 — 
  • September 30, 2024
  • Therapeutic Areas: Hematologic Oncology, Oncology
  • Specialties: NSCLC, Oncology
  • Location: Internet Activity Enduring
This educational initiative is designed for community-based oncology clinicians (physicians, nurse practitioners [NPs], physician assistants [PAs], pharmacists, and nurses) to enhance outcomes for individuals with who provide care for individuals with mNSCLC. This interactive online activity uses the game-based platform Kahoot! to test participant ability to identify and apply key learning points while competing against their colleagues. Expert faculty will discuss the emerging efficacy and safety data for CTLA-4 inhibitor combination regimens in metastatic NSCLC (mNSCLC) and explore strategies to identify patients who would most benefit from these therapies through the use of biomarkers. Additionally, there will be an in-depth discussion regarding approaches to effectively collaborate with other clinicians and mNSCLC patients to provide cost-effective, equitable, and inclusive care for patients of all socioeconomic and racial/ethnic backgrounds. Join us for Part 2 of this question and answer based educational activity, Improving Survival in First-line Metastatic NSCLC with Dual Checkpoint Blockade: Real-world Applications in Clinical Practice to apply the evidence to real-world patient cases!
Access Course
  • On-Demand
Weight Management as a Treatment for T2D: Novel Pharmacological Approaches
  • Credit: 0.50hr(s)
  • AAFP, AAPA, ABIM, CME, IPCE, MOC
  • April 30, 2024 — 
  • October 31, 2025
  • Therapeutic Areas: Diabetes, Family Medicine / Primary Care, Obesity
  • Specialties: Diabetes, Endocrinology, Obesity, Primary Care
  • Location: Internet Activity Enduring
Healthcare providers (HCPs) encounter significant challenges when treating patients with type 2 diabetes (T2D). HCPs should be cognizant of when to change or intensify treatment and be aware of options that are non-optimal. As such, HCPs need to be equipped with current professional guidelines, the latest clinical evidence on new and emerging therapies for T2D, and strategies for engaging patients in shared decision-making to effectively prioritize weight management and promote comprehensive T2D care.
Access Course
  • On-Demand
Advances in Non-Hodgkin Lymphoma Care: Navigating New and Emerging Treatments
  • Credit: 0.25hr(s)
  • AAPA, ABIM, CME, CPE, MOC, NCPD, Royal College MOC 
  • May 15, 2024 — 
  • May 14, 2025
  • Therapeutic Areas: Pan Tumor, Pathology, Pharmacy
  • Specialties: Pathology, Pharmacy
  • Location: Internet Activity Enduring
In this first episode, “Making the Right Selection: Expert Guidance on Treatment Sequencing of T-cell Mediated Therapies,” from the 4-part series Med Table Talk, “The Power of the Community: Translating Innovations into Care in NHL and HL,” learn from expert faculty about unmet needs for patients with NHL based on an understanding of disease- and patient-related characteristics. Additionally, learn how to best assess eligible patients among new and emerging CAR T-cell and bispecific antibody therapies. Expert faculty will also discuss both the mechanisms of action of CAR T-cell and bispecific antibodies. This episode will conclude with a patient case study, which will consist of a dialogue between faculty.
Access Course
  • On-Demand
Understanding the Impact of Weight on T2D Outcomes
  • Credit: 0.50hr(s)
  • AAFP, AAPA, ABIM, CME, IPCE, MOC
  • April 30, 2024 — 
  • October 31, 2025
  • Therapeutic Areas: Diabetes, Family Medicine / Primary Care, Obesity
  • Specialties: Diabetes, Endocrinology, Obesity, Primary Care
  • Location: Internet Activity Enduring
Healthcare providers (HCPs) encounter significant challenges when treating patients with type 2 diabetes (T2D). HCPs should be cognizant of when to change or intensify treatment and be aware of options that are non-optimal. As such, HCPs need to be equipped with current professional guidelines, the latest clinical evidence on new and emerging therapies for T2D, and strategies for engaging patients in shared decision-making to effectively prioritize weight management and promote comprehensive T2D care.
Access Course
View All MLI Activities
Facebook Twitter Linkedin Instagram
Subscribe to Mailing List
Scroll to Top